Skip to content

Christopher G. Davey

6 papers in the library · 665 citations · publishing 2016-2025

Papers

Sort Most recent Most cited

Safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in post-traumatic stress disorder: An overview of systematic reviews and meta-analyses.

The Australian and New Zealand journal of psychiatry April 1, 2025 Alene Sze Jing Yong, Suzie Bratuskins, Musa Samir Sultani et al. 16 citations

To critically evaluate published and unpublished systematic reviews and meta-analyses on the safety and efficacy of methylenedioxymethamphetamine-assisted psychotherapy for post-traumatic stress disorder. Six bibliometric databases and grey literature were searched from inception to 9 May 2024 for systematic reviews on the safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted...

Towards an expanded neurocognitive account of ketamine's rapid antidepressant effects.

The International Journal of Neuropsychopharmacology February 4, 2025 Yingliang Dai, Ben J. Harrison, Christopher G. Davey et al. 6 citations

Ketamine is an N-methyl-D-aspartate receptor antagonist that has shown effectiveness as a rapidly acting treatment for depression. Although advances have been made in understanding ketamine's antidepressant pharmacological and molecular mechanisms of action, the large-scale neurocognitive mechanisms driving its therapeutic effects are less clearly understood. To help provide such a framework,...

Ensuring the affordable becomes accessible-lessons from ketamine, a new treatment for severe depression.

The Australian and New Zealand journal of psychiatry February 1, 2024 Anthony Rodgers, Dilara Bahceci, Christopher G. Davey et al. 8 citations

In this paper, the case study of ketamine as a new treatment for severe depression is used to outline the challenges of repurposing established medicines and we suggest potential solutions. The antidepressant effects of generic racemic ketamine were identified over 20 years ago, but there were insufficient incentives for commercial entities to pursue its registration, or support for...

The self, neuroscience and psychosis study: Testing a neurophenomenological model of the onset of psychosis

Early Intervention in Psychiatry July 2, 2023 Marija Krcmar, Cassandra Wannan, Suzie Lavoie et al. 6 citations

AIM: Basic self disturbance is a putative core vulnerability marker of schizophrenia spectrum disorders. The primary aims of the Self, Neuroscience and Psychosis (SNAP) study are to: (1) empirically test a previously described neurophenomenological self-disturbance model of psychosis by examining the relationship between specific clinical, neurocognitive, and neurophysiological variables in UHR...

Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm

Australian & New Zealand Journal of Psychiatry March 21, 2021 Daniel Perkins, Jerome Sarris, Susan L. Rossell et al. 53 citations

The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine) is attracting renewed interest, driven by a pressing need for research and development of novel therapies for psychiatric disorders, as well as promising results of contemporary studies. In this Viewpoint, we reflect upon the ‘Clinical Memorandum on...

Mapping the self in the brain's default mode network

Neuroimage February 15, 2016 Christopher G. Davey, Jesus Pujol, Ben J. Harrison 576 citations

The brain's default mode network (DMN) has become closely associated with self-referential mental activity, particularly in the resting-state. While the DMN is important for such processes, it has functions other than self-reference, and self-referential processes are supported by regions outside of the DMN. In our study of 88 participants, we examined self-referential and resting-state...